Literature DB >> 30612715

Targeting Cancer Cell Dormancy.

Ariadna Recasens1, Lenka Munoz2.   

Abstract

Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to survive in a new environment and initiate metastasis, to become resistant to cancer therapy, and to evade immune destruction. Thus, dormant cancer cells are considered to be responsible for cancer progression. As we start to understand the mechanisms that enable quiescence, we can begin to develop pharmacological strategies to target dormant cancer cells. Herein, we summarize the major molecular mechanisms underlying the dormancy of disseminated tumor cells and drug-tolerant persister cells. We then analyze the current pharmacological strategies aimed (i) to keep cancer cells in the harmless dormant state, (ii) to reactivate dormant cells to increase their susceptibility to anti-proliferative drugs, and (iii) to eradicate dormant cancer cells.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer dormancy; disseminated tumor cells; drug-tolerant persister cells; epigenetic inhibitors

Mesh:

Substances:

Year:  2019        PMID: 30612715     DOI: 10.1016/j.tips.2018.12.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  76 in total

1.  Slow growth determines nonheritable antibiotic resistance in Salmonella enterica.

Authors:  Mauricio H Pontes; Eduardo A Groisman
Journal:  Sci Signal       Date:  2019-07-30       Impact factor: 8.192

Review 2.  Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer.

Authors:  Fabrizio Tabbò; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2019-11

Review 3.  KISS1 in metastatic cancer research and treatment: potential and paradoxes.

Authors:  Thuc Ly; Sitaram Harihar; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.

Authors:  Laura J Mauro; Megan I Seibel; Caroline H Diep; Angela Spartz; Carlos Perez Kerkvliet; Hari Singhal; Elizabeth M Swisher; Lauren E Schwartz; Ronny Drapkin; Siddharth Saini; Fatmata Sesay; Larisa Litovchick; Carol A Lange
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

6.  Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.

Authors:  Yuya Haga; Ilaria Marrocco; Ashish Noronha; Mary Luz Uribe; Nishanth Belugali Nataraj; Arunachalam Sekar; Diana Drago-Garcia; Simone Borgoni; Moshit Lindzen; Suvendu Giri; Stefan Wiemann; Yasuo Tsutsumi; Yosef Yarden
Journal:  Cancer Res       Date:  2021-05-03       Impact factor: 12.701

Review 7.  Harnessing the Co-vulnerabilities of Amino Acid-Restricted Cancers.

Authors:  Gaurav Pathria; Ze'ev A Ronai
Journal:  Cell Metab       Date:  2021-01-05       Impact factor: 27.287

8.  Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy.

Authors:  Sumaiyah K Rehman; Jennifer Haynes; Evelyne Collignon; Kevin R Brown; Yadong Wang; Allison M L Nixon; Jeffrey P Bruce; Jeffrey A Wintersinger; Arvind Singh Mer; Edwyn B L Lo; Cherry Leung; Evelyne Lima-Fernandes; Nicholas M Pedley; Fraser Soares; Sophie McGibbon; Housheng Hansen He; Aaron Pollet; Trevor J Pugh; Benjamin Haibe-Kains; Quaid Morris; Miguel Ramalho-Santos; Sidhartha Goyal; Jason Moffat; Catherine A O'Brien
Journal:  Cell       Date:  2021-01-07       Impact factor: 41.582

9.  Cellular plasticity in bone metastasis.

Authors:  Cao Fang; Yibin Kang
Journal:  Bone       Date:  2020-10-15       Impact factor: 4.398

10.  Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.

Authors:  Kwan Ho Tang; Shuai Li; Kwok-Kin Wong; Benjamin G Neel; Alireza Khodadadi-Jamayran; Jayu Jen; Han Han; Kayla Guidry; Ting Chen; Yuan Hao; Carmine Fedele; John A Zebala; Dean Y Maeda; James G Christensen; Peter Olson; Argus Athanas; Cynthia A Loomis; Aristotelis Tsirigos
Journal:  Cancer Discov       Date:  2021-08-05       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.